EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis

Pascal Heer iD, Clara Fernandez Elviro, Angela Koutsokera iD, Anne Mornand iD, Isabelle Rochat, Nicolas Regamey iD, Sylvain Blanchon iD

Therapeutic Advances in Respiratory Disease · 2025

DOI: 10.1177/17534666251376211 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Pascal Heer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology and Cystic Fibrosis Unit, Children's Hospital of Central Switzerland, Lucerne, Switzerland. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Aminophenols, Benzodioxoles. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation Respirer, Cystic Fibrosis Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are currently no early parameters that allow prediction of long-term responses to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator treatment on an individual level.

Objectives

To identify early parameters measured within 7 to 14 days after initiation of treatment with a CFTR modulator to assess CFTR modulator efficacy. Study design: Prospective observational study of patients diagnosed with CF who begin elexacaftor/tezacaftor/ivacaftor (ETI) therapy at 3 CF clinics in Switzerland (Geneva, Lausanne, Lucerne).

Methods

Standardized measurements were taken within 2 months prior to and 7 to 14 days after starting CFTR modulator treatment.

Results

ETI treatment was started on 47 patients [median age: 12 years] of whom 12 (26%) were switching from lumacaftor/ivacaftor ( n = 8) or tezacaftor/ivacaftor ( n = 4) to ETI. A significant early treatment effect was observed for BMI z -score ( p < 0.001) and inflammatory parameters (white blood cells ( p = 0.006), neutrophils ( p = 0.006), immunoglobulin G ( p = 0.012), and fecal calprotectin ( p = 0.002)). In CFTR functional assays, sweat chloride concentration and nasal potential difference testing [Δlow-chloride+isoproterenol, Sermet score, and Wilschanski index] improved significantly (all p < 0.001). Improvement was also observed in lung function (FVC, FEV 1 , MMEF 25-75 , LCI 2.5% ) (all p < 0.001). No changes were found for blood pressure, SpO 2 , respiratory rate, erythrocyte sedimentation rate, C-reactive protein, and fecal elastase.

Conclusion

This study identified clinical, biologic, and functional parameters showing treatment effect early after initiation of CFTR modulator therapy. These parameters may serve as potential predictors of long-term responses to CFTR modulator treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesQuinolonesAminopyridinesIndolesChloride Channel AgonistsPyrazolesHumansMaleFemaleProspective StudiesChildBiomarkersAdolescentTreatment OutcomeTime FactorsDrug CombinationsYoung AdultSweatAdultPyrrolidines

Stichwörter der Autor:innen

CFTR modulator treatmentelexacaftorivacaftornasal potential differenceshort-term responsetezacaftor

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesQuinolonesBiomarkersAminopyridinesCFTR protein, humanIndolesChloride Channel AgonistsDrug Combinations

Autor:innen und Institutionen

  • Pediatric Pulmonology and Cystic Fibrosis Unit, Children's Hospital of Central Switzerland, Lucerne, Switzerland.
  • Pediatric Pulmonology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Adult Cystic Fibrosis and CFTR-related disorders Center, Lung Transplant Center, Division of Pulmonology, Lausanne University Hospital and University of Lausanne, Switzerland.
  • Pediatric Pulmonology and Cystic Fibrosis Unit, University Hospital of Geneva, Geneva, Switzerland.
  • Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

ORCID-Profile: Pascal Heer, Angela Koutsokera, Anne Mornand, Nicolas Regamey, Sylvain Blanchon

Förderung

  • Fondation Respirer
  • Cystic Fibrosis Switzerland

Zitieren

APA

Heer, P., Fernandez Elviro, C., Koutsokera, A., Mornand, A., Rochat, I., Regamey, N., & Blanchon, S. (2025). Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251376211

Vancouver

Heer P, Fernandez Elviro C, Koutsokera A, Mornand A, Rochat I, Regamey N, et al. Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251376211

BibTeX
@article{Heer2025,
  author = {Heer, Pascal and Fernandez Elviro, Clara and Koutsokera, Angela and Mornand, Anne and Rochat, Isabelle and Regamey, Nicolas and Blanchon, Sylvain},
  title = {Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  doi = {10.1177/17534666251376211}
}
Kostenlos starten →